Division of Dermatology, University Medicine Cluster, National University Health Systems, Singapore.
Dermatol Ther. 2020 Nov;33(6):e14447. doi: 10.1111/dth.14447. Epub 2020 Oct 31.
Alopecia areata (AA) is a common cause of nonscarring hair loss. Diphenylcyclopropenone (DPCP) is a form of contact immunotherapy used in the treatment of AA. We retrospectively reviewed all patients who were diagnosed with AA over a 4-year period (1st January 2012 to 31st December 2015) and who have received DPCP. Forty patients were studied in total. The mean duration of disease prior to the study was 195 days. Patients received a mean number of 14.91 sessions (range: 1-65). The mean number of sessions required before clinical response was seen was 2.33 sessions, corresponding to 0.001% DPCP. Based on the modified Global Assessment Grading System, 33.5% (n = 11) of the patients experienced less than 25% improvement, 48.5% (n = 16) experienced 25%-74% improvement and 18.3% (n = 6) experienced more than 75% improvement. One patient had severe sensitisation reaction amounting to near erythroderma which resolved completely upon cessation of DPCP therapy. No other adverse reactions were noted in the cohort. DPCP remains a valuable tool in a dermatologist's armamentarium in treating alopecia areata as it is safe, well-tolerated, and shows limited efficacy.
斑秃（AA）是一种常见的非瘢痕性脱发原因。二苯基环丙烯酮（DPCP）是一种接触免疫疗法，用于治疗 AA。我们回顾性分析了在 4 年期间（2012 年 1 月 1 日至 2015 年 12 月 31 日）被诊断为 AA 并接受 DPCP 治疗的所有患者。共有 40 名患者接受了研究。研究前疾病的平均持续时间为 195 天。患者平均接受了 14.91 次治疗（范围：1-65 次）。在看到临床反应之前，平均需要进行 2.33 次治疗，相当于 0.001%的 DPCP。根据改良的全球评估分级系统，33.5%（n = 11）的患者改善小于 25%，48.5%（n = 16）的患者改善 25%-74%，18.3%（n = 6）的患者改善超过 75%。1 名患者发生严重致敏反应，相当于接近红皮病，停止 DPCP 治疗后完全缓解。该队列中未观察到其他不良反应。DPCP 仍然是皮肤科医生治疗斑秃的有效工具，因为它安全、耐受良好，且疗效有限。
